New Delhi, Oct 16, 2025

Biocon chief Kiran Mazumdar-Shaw on Thursday lauded a breakthrough antibody optimisation mechanism developed by US researchers, which can boost treatment for patients battling treatment-resistant tumours.

Researchers at the University of California at San Diego have developed a new approach that tackled a key driver of treatment resistance and metastasis — a protein called integrin Alpha-v-beta3.

The new method fights the protein by taking advantage of the tumour’s own immune landscape.

“In a breakthrough from UC San Diego School of Medicine, researchers have developed an antibody optimisation mechanism that could help tackle treatment-resistant tumours,” Mazumdar-Shaw said in a post on social media platform X.

“It can potentially boost current immunotherapies

See Full Page